Surgery and doxorubicin in dogs with hemangiosarcoma

Forty‐six dogs with histologically confirmed hemangiosarcoma of various locations other than skin were used in a prospective study to determine the efficacy of adjuvant doxorubicin (30 mg/m2 IV q 3 weeks for 5 treatments) 10 to 14 days after the tumor was partially or completely excised. Analysis of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary internal medicine 1996-11, Vol.10 (6), p.379-384
Main Authors: Ogilvie, G.K. (Colorado State University, Fort Collins, CO.), Powers, B.E, Mallinckrodt, C.H, Withrow, S.J
Format: Article
Language:English
Subjects:
Animals
ANTIBIOTICOS
ANTIBIOTICS
ANTIBIOTIQUE
Antineoplastic Agents - therapeutic use
CHIEN
COMBINATION THERAPY
Combined Modality Therapy
Disease-Free Survival
Dog Diseases - drug therapy
Dog Diseases - pathology
Dog Diseases - surgery
DOGS
Dose-Response Relationship, Drug
Doxorubicin - therapeutic use
Female
Heart Neoplasms - drug therapy
Heart Neoplasms - surgery
Heart Neoplasms - veterinary
Hemangiosarcoma - drug therapy
Hemangiosarcoma - surgery
Hemangiosarcoma - veterinary
Male
OPERACIONES QUIRURGICAS
OPERATION CHIRURGICALE
PERRO
Prognosis
Prospective Studies
Regression Analysis
SARCOMA
SARCOME
Splenic Neoplasms - drug therapy
Splenic Neoplasms - surgery
Splenic Neoplasms - veterinary
SUPERVIVENCIA
SURGICAL OPERATIONS
SURVIE
SURVIVAL
Survival Rate
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty‐six dogs with histologically confirmed hemangiosarcoma of various locations other than skin were used in a prospective study to determine the efficacy of adjuvant doxorubicin (30 mg/m2 IV q 3 weeks for 5 treatments) 10 to 14 days after the tumor was partially or completely excised. Analysis of the data included information on variables that were hypothesized to influence response to therapy, disease‐free interval (DFI), or survival time (ST). Other information collected included age, gender, breed, weight, prior therapy, type of surgery, location of the primary tumor, presence of metastases, number of doses of doxorubicin, response to doxorubicin therapy (complete or partial response!, and the following histological criteria: overall differentiation, nuclear pleomorphism, percent necrosis, mitotic score, total histological score, and grade. Surgery outcome (complete versus incomplete surgical excision) markedly influenced survival times (P < .001). Twenty percent of the dogs rendered free of disease were alive at 1 year, whereas none of the dogs that had residual tumor after surgery were alive at 1 year. Most of the histological criteria (nuclear pleomorphism, mitotic score, grade, overall differentiation) had marked (P < .05), or close to marked, independent associations with ST for dogs that had complete tumor removal. Results from analysis of DFI were generally similar to those of ST in dogs with complete excision of the tumor. Twenty‐seven of the 46 dogs (58.7%) had all clinical evidence of tumor successfully removed. Logistic regression analysis of surgical outcome (ability to remove all visible tumor) suggested that age of the subject was the only factor markedly influencing surgical outcome (P= .017). As age increased, the probability of success increased. Those dogs that had previous treatment for their hemangiosarcoma tended (P= .08) to have a shorter DFI and ST. Therefore, complete removal of all evidence of tumor followed by 5 doses of doxorubicin may be an effective treatment for dogs with hemangiosarcoma. Dogs that had all tumor successfully removed had a mean and median ST of 267 and 172 days, respectively. Dogs with incomplete tumor removal had a mean and median ST of 172 and 60 days, respectively. Similarly, prognostic variables such as the ability to completely excise all evidence of tumor, histological criteria, and age of the patient are potentially important prognostic variables for predicting outcome.
ISSN:0891-6640
1939-1676
DOI:10.1111/j.1939-1676.1996.tb02085.x